Literature DB >> 19030002

Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.

M P Kelly1, J M Stein, C G Vecsey, C Favilla, X Yang, S F Bizily, M F Esposito, G Wand, S J Kanes, T Abel.   

Abstract

Schizophrenia is a widespread psychiatric disorder, affecting 1% of people. Despite this high prevalence, schizophrenia is not well treated because of its enigmatic developmental origin. We explore here the developmental etiology of endophenotypes associated with schizophrenia using a regulated transgenic approach in mice. Recently, a polymorphism that increases mRNA levels of the G-protein subunit Galphas was genetically linked to schizophrenia. Here we show that regulated overexpression of Galphas mRNA in forebrain neurons of mice is sufficient to cause a number of schizophrenia-related phenotypes, as measured in adult mice, including sensorimotor gating deficits (prepulse inhibition of acoustic startle, PPI) that are reversed by haloperidol or the phosphodiesterase inhibitor rolipram, psychomotor agitation (hyperlocomotion), hippocampus-dependent learning and memory retrieval impairments (hidden water maze, contextual fear conditioning), and enlarged ventricles. Interestingly, overexpression of Galphas during development plays a significant role in some (PPI, spatial learning and memory and neuroanatomical deficits) but not all of these adulthood phenotypes. Pharmacological and biochemical studies suggest the Galphas-induced behavioral deficits correlate with compensatory decreases in hippocampal and cortical cyclic AMP (cAMP) levels. These decreases in cAMP may lead to reduced activation of the guanine exchange factor Epac (also known as RapGEF 3/4) as stimulation of Epac with the select agonist 8-pCPT-2'-O-Me-cAMP increases PPI and improves memory in C57BL/6J mice. Thus, we suggest that the developmental impact of a given biochemical insult, such as increased Galphas expression, is phenotype specific and that Epac may prove to be a novel therapeutic target for the treatment of both developmentally regulated and non-developmentally regulated symptoms associated with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19030002      PMCID: PMC3312743          DOI: 10.1038/mp.2008.124

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  109 in total

1.  A study on the role of the dorsal striatum and the nucleus accumbens in allocentric and egocentric spatial memory consolidation.

Authors:  Elvira De Leonibus; Alberto Oliverio; Andrea Mele
Journal:  Learn Mem       Date:  2005-09-15       Impact factor: 2.460

2.  The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample.

Authors:  Piercarlo Minoretti; Pierluigi Politi; Enrico Coen; Clara Di Vito; Marco Bertona; Marika Bianchi; Enzo Emanuele
Journal:  Neurosci Lett       Date:  2006-01-06       Impact factor: 3.046

3.  Double dissociation between hippocampal and prefrontal lesions on an operant delayed matching task and a water maze reference memory task.

Authors:  Hazel L Sloan; Mark Good; Stephen B Dunnett
Journal:  Behav Brain Res       Date:  2006-05-04       Impact factor: 3.332

4.  Targeted knockdown of G protein subunits selectively prevents receptor-mediated modulation of effectors and reveals complex changes in non-targeted signaling proteins.

Authors:  Andrejs M Krumins; Alfred G Gilman
Journal:  J Biol Chem       Date:  2006-01-30       Impact factor: 5.157

5.  Hippocampal and parahippocampal volumes in schizophrenia: a structural MRI study.

Authors:  Kang Sim; Iain DeWitt; Tali Ditman; Martin Zalesak; Ian Greenhouse; Donald Goff; Anthony P Weiss; Stephan Heckers
Journal:  Schizophr Bull       Date:  2005-11-30       Impact factor: 9.306

6.  Subchronic rolipram delivery activates hippocampal CREB and arc, enhances retention and slows down extinction of conditioned fear.

Authors:  Barbara Monti; Chiara Berteotti; Antonio Contestabile
Journal:  Neuropsychopharmacology       Date:  2006-02       Impact factor: 7.853

7.  The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.

Authors:  Gerhard Gründer; Christian Landvogt; Ingo Vernaleken; Hans-Georg Buchholz; Jasmin Ondracek; Thomas Siessmeier; Sebastian Härtter; Mathias Schreckenberger; Peter Stoeter; Christoph Hiemke; Frank Rösch; Dean F Wong; Peter Bartenstein
Journal:  Neuropsychopharmacology       Date:  2006-05       Impact factor: 7.853

Review 8.  Schizophrenia susceptibility genes: emergence of positional candidates and future directions.

Authors:  Joseph A Gogos; David J Gerber
Journal:  Trends Pharmacol Sci       Date:  2006-03-13       Impact factor: 14.819

Review 9.  Keynote review: phosphodiesterase-4 as a therapeutic target.

Authors:  Miles D Houslay; Peter Schafer; Kam Y J Zhang
Journal:  Drug Discov Today       Date:  2005-11-15       Impact factor: 7.851

10.  DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling.

Authors:  J Kirsty Millar; Benjamin S Pickard; Shaun Mackie; Rachel James; Sheila Christie; Sebastienne R Buchanan; M Pat Malloy; Jennifer E Chubb; Elaine Huston; George S Baillie; Pippa A Thomson; Elaine V Hill; Nicholas J Brandon; Jean-Christophe Rain; L Miguel Camargo; Paul J Whiting; Miles D Houslay; Douglas H R Blackwood; Walter J Muir; David J Porteous
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

View more
  34 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

2.  Exchange protein activated by cAMP enhances long-term memory formation independent of protein kinase A.

Authors:  Nan Ma; Ted Abel; Pepe J Hernandez
Journal:  Learn Mem       Date:  2009-05-23       Impact factor: 2.460

3.  Dosage sensitivity intolerance of VIPR2 microduplication is disease causative to manifest schizophrenia-like phenotypes in a novel BAC transgenic mouse model.

Authors:  Xinli Tian; Adam Richard; Madison Wynne El-Saadi; Aakriti Bhandari; Brian Latimer; Isabella Van Savage; Kevlyn Holmes; Ronald L Klein; Donard Dwyer; Nicholas E Goeders; X William Yang; Xiao-Hong Lu
Journal:  Mol Psychiatry       Date:  2019-08-23       Impact factor: 15.992

4.  Postnatal ethanol exposure alters levels of 2-arachidonylglycerol-metabolizing enzymes and pharmacological inhibition of monoacylglycerol lipase does not cause neurodegeneration in neonatal mice.

Authors:  Shivakumar Subbanna; Delphine Psychoyos; Shan Xie; Balapal S Basavarajappa
Journal:  J Neurochem       Date:  2015-04-30       Impact factor: 5.372

Review 5.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 6.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

Review 7.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

Review 8.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

9.  Social, communication, and cortical structural impairments in Epac2-deficient mice.

Authors:  Deepak P Srivastava; Kelly A Jones; Kevin M Woolfrey; Jeffrey Burgdorf; Theron A Russell; Abigail Kalmbach; Hyerin Lee; Connie Yang; Mazdak M Bradberry; David Wokosin; Joseph R Moskal; Manuel F Casanova; Jack Waters; Peter Penzes
Journal:  J Neurosci       Date:  2012-08-22       Impact factor: 6.167

10.  Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines.

Authors:  Kevin M Woolfrey; Deepak P Srivastava; Huzefa Photowala; Megumi Yamashita; Maria V Barbolina; Michael E Cahill; Zhong Xie; Kelly A Jones; Lawrence A Quilliam; Murali Prakriya; Peter Penzes
Journal:  Nat Neurosci       Date:  2009-09-06       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.